Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.
You may also be interested in...
Advisory Committee Discussions Will Be Key Tool In Developing REMS
Drug sponsors need not fear an advisory committee discussion about how to ensure safe use of their products, William Pullman, Chief Development Officer at Dyax, told a Jan. 13 Windhover webinar on surviving an advisory committee
Advisory Committee Discussions Will Be Key Tool In Developing REMS
Drug sponsors need not fear an advisory committee discussion about how to ensure safe use of their products, William Pullman, Chief Development Officer at Dyax, told a Jan. 13 Windhover webinar on surviving an advisory committee
Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks
Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older